PitchBook clients can access the full report and Excel data pack via the Research Center on the PitchBook Platform.
Pharma biotools VC holds at $1.3 billion as deal count drops 19%
Pharma biotools VC investment held at $1.3 billion across 126 deals in Q2 2026, marking the sixth straight quarter above $1 billion. Deal count fell 19% from Q1, however, dropping back to post-pandemic norms, as the broader biopharma funding recovery has yet to reach the tools sector. Services led all segments at $502 million, powered by Cellares’ Series D extension ahead of a planned 2027 IPO. Platforms & reagents overtook in silico discovery for the first time in recent memory, taking second place at $330 million across 29 deals. On the M&A side, Merck KGaA’s $11.3 billion agreement to acquire Bio-Techne headlined strategic consolidation, as established players have been buying up reagent and assay platforms to control complete discovery workflows.
The bigger story is where the money is going: VC is bifurcating across the vertical. Asset-light AI platforms are capturing outsized early rounds. Chai Discovery’s $400 million Series C landed just after quarter-end, with Lila Sciences reportedly pursuing a $2 billion Series B. Meanwhile, capital-intensive platforms are scaling toward a stricter exit bar. Tech-oriented syndicates are driving these mega-rounds, and traditional biopharma venture funds have largely stayed out. Frontier AI labs are emerging as a new acquirer class, with NVIDIA’s BioNeMo Agent Toolkit commoditizing baseline model capability from below. The Q2 2026 Pharma Biotools Report includes segment-level deal data, valuation benchmarks, and exit analysis.
Annualized H1 2026 deal activity falls behind 2025 totals as the vertical lags the biopharma recovery.